This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (103)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Menopause  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic

Bruce M. Psaty, MD,PhD; Nicholas L. Smith, PhD; Rozenn N. Lemaitre, PhD; Hans L. Vos, PhD; Susan R. Heckbert, MD,PhD; Andrea Z. LaCroix, PhD; Frits R. Rosendaal, MD,PhD

JAMA. 2001;285:906-913.

Context  Estrogens are known to be prothrombotic, and findings from the Heart and Estrogen/progestin Replacement Study suggest that in women with clinically recognized heart disease, hormone replacement therapy (HRT) may be associated with early harm and late benefit in terms of coronary events.

Objective  To assess whether, as hypothesized, prothrombotic mutations modify the association between HRT use and incidence of first myocardial infarction (MI).

Design and Setting  Population-based, case-control study conducted in a Seattle-based health maintenance organization.

Participants  Cases were 232 postmenopausal women aged 30 to 79 years who had their first nonfatal MI between 1995 and 1998. Controls were a stratified random sample of 723 postmenopausal women without MI who were frequency-matched to cases by age, calendar year, and hypertension status.

Main Outcome Measure  Risk of first nonfatal MI based on current use of HRT and the presence or absence of coagulation factor V Leiden and prothrombin 20210 GA variants among cases and controls, stratified by hypertension.

Results  One hundred eight MI cases and 387 controls had hypertension and 124 MI cases and 336 controls did not. Among hypertensive women, the prothrombin variant was a risk factor for MI (odds ratio [OR], 4.32; 95% confidence interval [CI], 1.52-12.1) and, in this stratum, there was also a significant interaction between use of HRT and presence of the prothrombin variant on risk of MI. Compared with nonusers of HRT with wild-type genotype, women who were current users and who had the prothrombin variant (n = 8) had a nearly 11-fold increase in risk of a nonfatal MI (OR, 10.9; 95% CI, 2.15-55.2). The interaction with the prothrombin variant was more pronounced in analyses assuming 100% compliance than in those assuming 80% compliance with HRT. The interaction was absent among nonhypertensive women and was less pronounced if hypertensive and nonhypertensive women were combined into 1 group. No interaction was found for factor V Leiden in either hypertensive or nonhypertensive women. Among hypertensive women, the estimates were affected only in trivial ways by adjustment, and the interaction with the prothrombin variant was specific to HRT.

Conclusions  Our results suggest that among postmenopausal hypertensive women, the association between HRT use and MI risk differed between those with and without the prothrombin 20210 GA variant. If these findings are confirmed in other studies, screening for the prothrombin variant may permit a better assessment of the risks and benefits associated with HRT in postmenopausal women.

Author Affiliations: Departments of Medicine (Drs Psaty and Lemaitre), Epidemiology (Drs Psaty, Smith, Heckbert, LaCroix, and Rosendaal), and Health Services (Dr Psaty), Cardiovascular Health Research Unit, University of Washington, Seattle; Fred Hutchinson Cancer Research Center, Seattle, Wash (Dr LaCroix); Center for Health Studies, Group Health Cooperative, Seattle, Wash (Dr LaCroix); Department of Hematology (Drs Vos and Rosendaal), and Clinical Epidemiology (Dr Rosendaal), Leiden University Medical Center, Leiden, the Netherlands.

RELATED ARTICLE

February 21, 2001
JAMA. 2001;285(7):955-956.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Renin-Angiotensin System Haplotypes and the Risk of Myocardial Infarction and Stroke in Pharmacologically Treated Hypertensive Patients
Marciante et al.
Am J Epidemiol 2007;166:19-27.
ABSTRACT | FULL TEXT  

Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials
Wierman and Kohrt
Reproductive Sciences 2007;14:300-314.
ABSTRACT  

Effect of genetic variations in platelet glycoproteins Ib{alpha} and VI on the risk for coronary heart disease events in postmenopausal women taking hormone therapy
Bray et al.
Blood 2007;109:1862-1869.
ABSTRACT | FULL TEXT  

Advancing the Study of Stroke in Women: Summary and Recommendations for Future Research From an NINDS-Sponsored Multidisciplinary Working Group
Bushnell et al.
Stroke 2006;37:2387-2399.
ABSTRACT | FULL TEXT  

Common Genetic Variation in the Prothrombin Gene, Hormone Therapy, and Incident Nonfatal Myocardial Infarction in Postmenopausal Women
Hindorff et al.
Am J Epidemiol 2006;163:600-607.
ABSTRACT | FULL TEXT  

Vascular consequences of menopause and hormone therapy: Importance of timing of treatment and type of estrogen
Dubey et al.
Cardiovasc Res 2005;66:295-306.
ABSTRACT | FULL TEXT  

Serum Lipid Levels and the Risk of Venous Thrombosis
Doggen et al.
Arterioscler. Thromb. Vasc. Bio. 2004;24:1970-1975.
ABSTRACT | FULL TEXT  

Cardiology: the past, the present, and the future
Braunwald
J Am Coll Cardiol 2003;42:2031-2041.
FULL TEXT  

An Epidemiologist Looks at Hormones and Heart Disease in Women
Barrett-Connor
J. Clin. Endocrinol. Metab. 2003;88:4031-4042.
FULL TEXT  

Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson et al.
NEJM 2003;349:523-534.
ABSTRACT | FULL TEXT  

Effect of Long-Term Hormone Replacement Therapy on Atherosclerosis Progression in Postmenopausal Women Relates to Myeloperoxidase Promoter Polymorphism
Makela et al.
J. Clin. Endocrinol. Metab. 2003;88:3823-3828.
ABSTRACT | FULL TEXT  

Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction
Reiner et al.
Blood 2003;102:25-30.
ABSTRACT | FULL TEXT  

Toward a Causal Model of Cardiovascular Responses to Stress and the Development of Cardiovascular Disease
Schwartz et al.
Psychosom. Med. 2003;65:22-35.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Risk of Cardiovascular Disease: Implications of the Results of the Women's Health Initiative
Kuller
Arterioscler. Thromb. Vasc. Bio. 2003;23:11-16.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Associated Risk of Stroke in Postmenopausal Women
Lemaitre et al.
Arch Intern Med 2002;162:1954-1960.
ABSTRACT | FULL TEXT  

Update in General Internal Medicine
Lucey and Cole
ANN INTERN MED 2002;137:334-340.
FULL TEXT  

Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease
Humphrey et al.
ANN INTERN MED 2002;137:273-284.
ABSTRACT | FULL TEXT  

Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
Grady et al.
JAMA 2002;288:49-57.
ABSTRACT | FULL TEXT  

Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)
Hulley et al.
JAMA 2002;288:58-64.
ABSTRACT | FULL TEXT  

Factor V Leiden: The Copenhagen City Heart Study and 2 meta-analyses
Juul et al.
Blood 2002;100:3-10.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and the Factor V Leiden Mutation
Bauer
Arterioscler. Thromb. Vasc. Bio. 2002;22:879-880.
FULL TEXT  

Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Ischemic Stroke in Postmenopausal Women
Lemaitre et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:1051-1052.
FULL TEXT  

Diuretic Therapy, the {alpha}-Adducin Gene Variant, and the Risk of Myocardial Infarction or Stroke in Persons With Treated Hypertension
Psaty et al.
JAMA 2002;287:1680-1689.
ABSTRACT | FULL TEXT  

Individualized Hormone-Replacement Therapy?
Krauss
NEJM 2002;346:1017-1018.
FULL TEXT  

Interaction of Hemostatic Genetics With Hormone Therapy : New Insights To Explain Arterial Thrombosis in Postmenopausal Women
Braunstein et al.
Chest 2002;121:906-920.
ABSTRACT | FULL TEXT  

Hormones, genetic factors, and gender differences in cardiovascular disease
Rossouw
Cardiovasc Res 2002;53:550-557.
FULL TEXT  

Female Hormones and Thrombosis
Rosendaal et al.
Arterioscler. Thromb. Vasc. Bio. 2002;22:201-210.
ABSTRACT | FULL TEXT  

Genome and Hormones: Gender Differences in Physiology: Invited Review: Pharmacogenetics of estrogen replacement therapy
Herrington and Klein
J. Appl. Physiol. 2001;91:2776-2784.
ABSTRACT | FULL TEXT  

Hormone Replacement Therapy and Cardiovascular Disease: A Statement for Healthcare Professionals From the American Heart Association
Mosca et al.
Circulation 2001;104:499-503.
FULL TEXT  

Postmenopausal Hormone-Replacement Therapy
Manson and Martin
NEJM 2001;345:34-40.
FULL TEXT  

Postmenopausal hormones and heart disease
Grady and Hulley
J Am Coll Cardiol 2001;38:8-10.
FULL TEXT  

Genetic Variant and HRT Use May Affect MI Risk in Postmenopausal Women
JWatch Women's Health 2001;2001:8-8.
FULL TEXT  

Genetic Variant and HRT Use May Affect MI Risk in Postmenopausal Women
Journal Watch Cardiology 2001;2001:10-10.
FULL TEXT  

Subgroup Interactions in the Heart and Estrogen/Progestin Replacement Study: Lessons Learned
Furberg et al.
Circulation 2002;105:917-922.
ABSTRACT | FULL TEXT